Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 8.01 (Other Events). VEPPANU license to Rigel became effective June 11, 2026 after HSR clearance.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- VEPPANU license to Rigel became effective June 11, 2026 after HSR clearance
- Arvinas and Pfizer received $70.0M upfront, split evenly under the agreement
- Additional $15.0M payment tied to successful development and manufacturing transition activities
- Up to $320.0M in contingent development, regulatory and commercial milestones
- Tiered royalties in the mid-teens to mid-20s on worldwide net sales, with future payments dependent on execution and commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.